Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi AppTec Says 2024 First Half Shows Stable Operations

publication date: Jul 29, 2024

WuXi AppTec, a large China CRDMO, announced flat earnings for the first six months of 2024 despite, as the company said, “external challenges.” The external challenges are the BIOSECURE Act currently being considered by the US Congress, which aims to stop US biopharma companies from using WuXi as a drug development partner. During the first half of the year, WuXi’s revenues dropped by only 1.2% from the year earlier. Its US customers provided $1.5 billion (62%) of the company’s income, a small decline. More details....



Share this with colleagues:

 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here